Avingtrans upgrades FY25 outlook with stronger EBITDA performance

Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced an update on current trading ahead of conclusion of the financial year ending 31 May 2025.

Based on unaudited management accounts for FY25, the Company now expects to report Adj. EBITDA¹ ahead of market expectations², driven by better than anticipated performance within the Advanced Engineering Systems (AES) division. Revenues are expected to be in-line².

Avingtrans intends to provide a more detailed update on current performance by way of a trading update to be published in mid June 2025.

¹Adjusted to add back amortisation of intangibles from business combinations, acquisition costs and exceptional items and discontinued operations.

² Prior to today’s announcement, the Company understands that market expectations for FY25 were Revenues of £161.0m and

Adj. EBITDA of £15.1m.

Share on:

You might also enjoy reading Avingtrans appoints Stuart Gall as CEO of Medical and Industrial Imaging division

Written by: Amilia Stone

Latest Company News

Avingtrans appoints Stuart Gall as CEO of Medical and Industrial Imaging division

January 12, 2026

Avingtrans plc has announced that Stuart Gall officially assumed the role of Chief Executive Officer of its medical and industrial imaging division on 1 January 2026.

Avingtrans subsidiary Adaptix gains FDA clearance for Ortho350

November 10, 2025

Avingtrans reported that its subsidiary Adaptix has received FDA 510(k) clearance for the Ortho350, a compact 3D orthopaedic imaging system designed for point of care use.

Avingtrans CEO on record revenue and strong order book momentum for FY25 (LON:AVG)

October 2, 2025

Avingtrans has delivered record revenue of £156.4 million for FY25, with Chief Executive Officer Steve McQuillan highlighting robust order book growth, major contract wins, and increasing demand across energy, defence, infrastructure and medical divisions.

Avingtrans appoints Stuart Gall as CEO of medical imaging division

September 29, 2025

Avingtrans Plc has announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses, including Adaptix and Magnetica, effective on or before 10 March 2026.

Avingtrans Plc Record Results, New Nuclear Wins and the Power of AI-Driven Demand (Video)

September 25, 2025

Avingtrans CEO Steve McQuillan shares how AI, energy and infrastructure megatrends are driving record results — and why strategic deals could be back on the table in FY26.

Avingtrans reports record revenue and earnings growth in FY25

September 24, 2025

Avingtrans posted preliminary results for the year ended 31 May 2025, with revenue up 14.5% to a record £156.4m and adjusted EBITDA rising to £16.7m. Adjusted profit before tax increased 18% to £8.6m, while diluted EPS grew 28% to 23.7p.